These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 26233509)

  • 21. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs.
    Fleischmann R; Cutolo M; Genovese MC; Lee EB; Kanik KS; Sadis S; Connell CA; Gruben D; Krishnaswami S; Wallenstein G; Wilkinson BE; Zwillich SH
    Arthritis Rheum; 2012 Mar; 64(3):617-29. PubMed ID: 21952978
    [TBL] [Abstract][Full Text] [Related]  

  • 22. One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled study.
    Genovese MC; Durez P; Richards HB; Supronik J; Dokoupilova E; Aelion JA; Lee SH; Codding CE; Kellner H; Ikawa T; Hugot S; Ligozio G; Mpofu S
    J Rheumatol; 2014 Mar; 41(3):414-21. PubMed ID: 24429175
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study.
    Furst DE; Saag K; Fleischmann MR; Sherrer Y; Block JA; Schnitzer T; Rutstein J; Baldassare A; Kaine J; Calabrese L; Dietz F; Sack M; Senter RG; Wiesenhutter C; Schiff M; Stein CM; Satoi Y; Matsumoto A; Caldwell J; Harris RE; Moreland LW; Hurd E; Yocum D; Stamler DA
    Arthritis Rheum; 2002 Aug; 46(8):2020-8. PubMed ID: 12209503
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intranasal administration of recombinant human cartilage glycoprotein-39 as a treatment for rheumatoid arthritis: a phase II, multicentre, double-blind, randomised, placebo-controlled, parallel-group, dose-finding trial.
    Landewé RB; Houbiers JG; Van den Bosch F; in't Hout J; Verschueren PC; Meijerink JH; van den Hoogen FH; Masek BA; Bruyn GA; Wouters JM; Voskuyl AE; van Laar JM; Bijlsma JJ; van der Heijde DM; Breedveld FC; van de Putte LB; Miltenburg AM; de Keyser F
    Ann Rheum Dis; 2010 Sep; 69(9):1655-9. PubMed ID: 19778914
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Subcutaneous abatacept for the treatment of rheumatoid arthritis: longterm data from the ACQUIRE trial.
    Genovese MC; Tena CP; Covarrubias A; Leon G; Mysler E; Keiserman M; Valente R; Nash P; Simon-Campos JA; Box J; Legerton CW; Nasonov E; Durez P; Delaet I; Teng J; Alten R
    J Rheumatol; 2014 Apr; 41(4):629-39. PubMed ID: 24584926
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors.
    Genovese MC; Fleischmann RM; Greenwald M; Satterwhite J; Veenhuizen M; Xie L; Berclaz PY; Myers S; Benichou O
    Ann Rheum Dis; 2013 Sep; 72(9):1461-8. PubMed ID: 23268367
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized controlled trial comparing 2 different starting doses of methotrexate in rheumatoid arthritis.
    Dhir V; Singla M; Gupta N; Goyal P; Sagar V; Sharma A; Khanna S; Singh S
    Clin Ther; 2014 Jul; 36(7):1005-15. PubMed ID: 24976447
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled study.
    Weinblatt ME; Schiff MH; Ruderman EM; Bingham CO; Li J; Louie J; Furst DE
    Arthritis Rheum; 2008 Jul; 58(7):1921-30. PubMed ID: 18576334
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial.
    Hørslev-Petersen K; Hetland ML; Junker P; Pødenphant J; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Schlemmer A; Dam MY; Hansen I; Horn HC; Ammitzbøll CG; Jørgensen A; Krintel SB; Raun J; Johansen JS; Østergaard M; Stengaard-Pedersen K;
    Ann Rheum Dis; 2014 Apr; 73(4):654-61. PubMed ID: 23434570
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial.
    Greenwald MW; Shergy WJ; Kaine JL; Sweetser MT; Gilder K; Linnik MD
    Arthritis Rheum; 2011 Mar; 63(3):622-32. PubMed ID: 21360491
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of belimumab in patients with rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled, dose-ranging Study.
    Stohl W; Merrill JT; McKay JD; Lisse JR; Zhong ZJ; Freimuth WW; Genovese MC
    J Rheumatol; 2013 May; 40(5):579-89. PubMed ID: 23547209
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MLN3897 plus methotrexate in patients with rheumatoid arthritis: safety, efficacy, pharmacokinetics, and pharmacodynamics of an oral CCR1 antagonist in a phase IIa, double-blind, placebo-controlled, randomized, proof-of-concept study.
    Vergunst CE; Gerlag DM; von Moltke L; Karol M; Wyant T; Chi X; Matzkin E; Leach T; Tak PP
    Arthritis Rheum; 2009 Dec; 60(12):3572-81. PubMed ID: 19950299
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study.
    Takeuchi T; Tanaka Y; Iwasaki M; Ishikura H; Saeki S; Kaneko Y
    Ann Rheum Dis; 2016 Jun; 75(6):1057-64. PubMed ID: 26672064
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial.
    Lambert CM; Sandhu S; Lochhead A; Hurst NP; McRorie E; Dhillon V
    Arthritis Rheum; 2004 Feb; 50(2):364-71. PubMed ID: 14872477
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study.
    Genovese MC; Durez P; Richards HB; Supronik J; Dokoupilova E; Mazurov V; Aelion JA; Lee SH; Codding CE; Kellner H; Ikawa T; Hugot S; Mpofu S
    Ann Rheum Dis; 2013 Jun; 72(6):863-9. PubMed ID: 22730366
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study.
    Glatt S; Taylor PC; McInnes IB; Schett G; Landewé R; Baeten D; Ionescu L; Strimenopoulou F; Watling MIL; Shaw S
    Ann Rheum Dis; 2019 Aug; 78(8):1033-1040. PubMed ID: 31177099
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents.
    Genovese MC; Kavanaugh A; Weinblatt ME; Peterfy C; DiCarlo J; White ML; O'Brien M; Grossbard EB; Magilavy DB
    Arthritis Rheum; 2011 Feb; 63(2):337-45. PubMed ID: 21279990
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 2 dosing regimens of fostamatinib in patients with rheumatoid arthritis with an inadequate response to a tumor necrosis factor-α antagonist.
    Genovese MC; van der Heijde DM; Keystone EC; Spindler AJ; Benhamou C; Kavanaugh A; Fudman E; Lampl K; O'Brien C; Duffield EL; Poiley J; Weinblatt ME
    J Rheumatol; 2014 Nov; 41(11):2120-8. PubMed ID: 25225285
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tramadol 37.5-mg/acetaminophen 325-mg combination tablets added to regular therapy for rheumatoid arthritis pain: a 1-week, randomized, double-blind, placebo-controlled trial.
    Lee EY; Lee EB; Park BJ; Lee CK; Yoo B; Lim MK; Shim SC; Sheen DH; Seo YI; Kim HA; Baek HJ; Song YW
    Clin Ther; 2006 Dec; 28(12):2052-60. PubMed ID: 17296461
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate.
    Genovese MC; Lee E; Satterwhite J; Veenhuizen M; Disch D; Berclaz PY; Myers S; Sides G; Benichou O
    Ann Rheum Dis; 2013 Sep; 72(9):1453-60. PubMed ID: 23599435
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.